These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7191289)

  • 101. Influence of variations in the chemical structure of heparin on its anticoagulant and anti-factor Xa activities.
    Ayotte L; Lormeau JC; Perlin AS
    Thromb Res; 1981 Apr 1-15; 22(1-2):97-102. PubMed ID: 7292448
    [No Abstract]   [Full Text] [Related]  

  • 102. Protamine sulfate titration for heparin activity in neonates with indwelling umbilical catheters.
    Hall RT; Rhodes PG; Turner EA; Braun WJ
    J Pediatr; 1976 Mar; 88(3):467-72. PubMed ID: 1245960
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
    Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Identification of a heparin activated amidolytic enzyme in carp (Cyprinus carpio) plasma.
    Atkinson PM; Walker NP; Niehaus A; Bradlow BA; Smith G
    Thromb Res; 1983 Feb; 29(3):289-97. PubMed ID: 6342205
    [TBL] [Abstract][Full Text] [Related]  

  • 105. [Studies on plasma hypercoagulability. 3. An improved method for plasma heparin determination based on metachromatic activity and its levels in human plasma].
    Satake K
    Naika Hokan; 1969 May; 16(5):173-81. PubMed ID: 5387636
    [No Abstract]   [Full Text] [Related]  

  • 106. Neutralization of heparin by histone and its subfractions.
    Pal PK; Starr T; Gertler MM
    Thromb Res; 1983 Jul; 31(1):69-79. PubMed ID: 6612698
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Are synthetic inhibitors able to improve factor Xa assays using peptide substrates?
    Stürzebecher J; Markwardt F; Wagner G; Voigt B
    Thromb Res; 1982 May; 26(3):221-6. PubMed ID: 7112515
    [No Abstract]   [Full Text] [Related]  

  • 108. In vitro evaluation of a biologic graft surface. Effect of treatment with conventional and low molecular weight (LMW) heparin.
    Björck CG; Bergqvist D; Esquivel CO; Larsson R; Rudsvik Y
    Thromb Res; 1984 Sep; 35(6):653-63. PubMed ID: 6506022
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Factor XIII assay by an isotope method. II. Heparin inhibition of factor XIII activation.
    Dvilansky A; Britten AF; Loewy AG
    Thromb Diath Haemorrh; 1970 Oct; 24(1):256-64. PubMed ID: 5483966
    [No Abstract]   [Full Text] [Related]  

  • 110. Laboratory evaluation of heparin therapy.
    Phillips JD
    Clin Lab Haematol; 1980; 2(1):53-62. PubMed ID: 7379468
    [TBL] [Abstract][Full Text] [Related]  

  • 111. [Different heparin fractions].
    Bychkov SM; Kharlamova VN
    Biull Eksp Biol Med; 1976 Mar; 81(3):289-91. PubMed ID: 953269
    [TBL] [Abstract][Full Text] [Related]  

  • 112. [Effect of heparin, protamine sulfate and pantrypin on the carbohydrate metabolism and noradrenaline content of the vascular wall].
    Smirnov PA
    Farmakol Toksikol; 1972; 35(2):225-8. PubMed ID: 5021662
    [No Abstract]   [Full Text] [Related]  

  • 113. Sustained increase in anti-Xa activity by low-dose heparin in medical patients.
    Lowe G; Belch J; Regan K; Forbes C; Prentice C
    Thromb Haemost; 1982 Jun; 47(3):296. PubMed ID: 7112504
    [No Abstract]   [Full Text] [Related]  

  • 114. Dissociation of the thrombin/antithrombin III reaction from amidolytic activity of the enzyme at high salt concentration.
    Oshima G
    Thromb Res; 1989 May; 54(3):225-35. PubMed ID: 2749614
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Comparison of a natural heparinoid with sodium and calcium heparin for their effect on the inhibitor of activated factor X.
    Mannucci PM; di Santo C; Franchi F
    Experientia; 1976 Nov; 32(11):1478-80. PubMed ID: 62674
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Mode of binding of histamine and some other biogenic amines to a protamine-heparin complex in vitro.
    Aborg CH; Uvnäs B
    Acta Physiol Scand; 1968 Dec; 74(4):552-67. PubMed ID: 5735618
    [No Abstract]   [Full Text] [Related]  

  • 117. Interaction of basic amino acids, polypeptides and proteins with heparin.
    Jooyandeh F; Moore JS; Davies JV
    Int J Radiat Biol Relat Stud Phys Chem Med; 1979 May; 35(5):487-91. PubMed ID: 313923
    [No Abstract]   [Full Text] [Related]  

  • 118. Biological properties of the naturally occurring plasma inhibitor to activated factor X.
    Yin ET; Wessler S; Stoll PJ
    J Biol Chem; 1971 Jun; 246(11):3703-11. PubMed ID: 5578915
    [No Abstract]   [Full Text] [Related]  

  • 119. [Synthesis of N-alpha-(arylsulfonylglycyl)-3-amidinophenylalanine esters as active and relatively specific inhibitors of factor Xa].
    Vieweg H; Wagner G
    Pharmazie; 1987 Apr; 42(4):268. PubMed ID: 3615560
    [No Abstract]   [Full Text] [Related]  

  • 120. Structural studies on a biologically active hexasaccharide obtained from heparin.
    Choay J; Lormeau JC; Petitou M; Sinaÿ P; Fareed J
    Ann N Y Acad Sci; 1981; 370():644-9. PubMed ID: 6943974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.